Health experts predict uptick in U.S. Covid cases due to new BA.2 variant

Health experts predict uptick in U.S. Covid cases due to new BA.2 variant


Dr. Anthony Fauci, White House Chief Medical Advisor and Director of the NIAID, responds to questions from Sen. Rand Paul (R-KY) at a Senate Health, Education, Labor, and Pensions Committee hearing on Capitol Hill on January 11, 2022 in Washington, D.C.

Getty Images

U.S. health experts are warning an emerging, highly contagious Covid omicron variant, called BA.2, could soon lead to another uptick in domestic coronavirus cases.

White House chief medical advisor Dr. Anthony Fauci said BA.2 is about 50% to 60% more transmissible than omicron, but it does not appear to be more severe. Health officials continue to stress coronavirus vaccines and boosters remain the best ways to prevent serious illness from the virus.

“It does have increased transmission capability,” Fauci said Sunday on ABC’s “This Week.” “However, when you look at the cases, they do not appear to be any more severe and they do not appear to evade immune responses either from vaccines or prior infections.”

The variant has already caused cases to increase in China and parts of Europe. It is estimated to account for about 25% or 30% of new cases in the U.S., but it could become the country’s most dominant variant, Fauci said.

Fauci said he expects “an uptick in cases” due to BA.2, but not necessarily a massive surge like other variants have caused. That’s despite the Centers for Disease Control and Prevention recently relaxing mask recommendations for most Americans.

U.S. Surgeon General Vivek Murthy and Dr. Scott Gottlieb, a board member of Covid vaccine maker Pfizer and a former head of the Food and Drug Administration, also expressed similar views on Sunday regarding BA.2.

Murthy said the variant could cause a new spike in cases but that the country is in a better position now than it was in the previous two years, when Covid-19 “defined our lives.”

“We should be prepared, Covid hasn’t gone away,” Murthy said during “Fox News Sunday.” “Our focus should be on preparation, not on panic.”

Gottlieb, echoing previous comments days before to CNBC, said he also expects “some uptick” due to BA.2 but “not a big wave of infection.”

“I think we’re going to continue to see low levels of infection through the summer. But before we get there, we’re probably going to see some tick-up of infection like the Europeans are seeing right now, maybe not as pronounced,” Gottlieb said Sunday during CBS’s “Face the Nation.”

The CDC reported more than 31,200 new Covid-19 cases Saturday, including 958 deaths. Both are significantly down from the beginning of the year.

Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus, health-care tech company Aetion and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings’ and Royal Caribbean’s “Healthy Sail Panel.”



Source

Abortion pill makers brace for restrictions a year after Trump’s election
Health

Abortion pill makers brace for restrictions a year after Trump’s election

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]

Read More
Republicans push Obamacare tax credit alternatives as enrollment deadline looms
Health

Republicans push Obamacare tax credit alternatives as enrollment deadline looms

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025 in Miami, Florida. Joe Raedle | Getty Images With enhanced Obamacare tax credits set to expire at the end of the year, Republicans are proposing new alternatives aimed at lowering the cost of health care. Their window for doing so is rapidly […]

Read More
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
Health

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]

Read More